Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Acquisition Of Kali Will Help Boost Product Offerings 50% In Two Years

This article was originally published in The Pink Sheet Daily

Executive Summary

Par will pay $135 mil. for the New Jersey-based generic drug firm. The combined company will have 37 pending ANDAs, including first-to-file application for generic version of J&J's Ultracet.
Advertisement

Related Content

FDA Rescinds Zofran ODT ANDA Approval
FDA Rescinds Zofran ODT ANDA Approval
Ultracet Generics Launch: Par Goes "At Risk," Ivax Has "Authorized" Generic
Ultracet Generics Launch: Par Goes "At Risk," Ivax Has "Authorized" Generic
Waxman/Hatch Reforms Preserve Declaratory Judgment “Reasonable Apprehension” Test – Court
Waxman/Hatch Reforms Preserve Declaratory Judgment “Reasonable Apprehension” Test – Court
Three Rivers/Par, Sandoz Ribavirin ANDAs Approved By FDA; Companies Will Share Exclusivity
Three Rivers/Par, Sandoz Ribavirin ANDAs Approved By FDA; Companies Will Share Exclusivity

Topics

Advertisement
UsernamePublicRestriction

Register

PS059098

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel